Arrakis Therapeutics, founded in Waltham, Massachusetts, is a biotechnology company dedicated to pioneering innovative RNA-targeted small molecule (rSM) medicines. Their core mission is to address global health challenges by developing novel therapeutics that target RNA, aiming to treat diseases that are currently difficult to manage with existing therapies. The company focuses on creating partnerships and collaborations to advance their scientific endeavors and bring transformative treatments to patients worldwide.

Notable affiliations include a multi-target collaboration with Amgen, a leading biotechnology firm, to identify novel RNA degrader small molecule therapeutics. Arrakis Therapeutics has garnered attention for its groundbreaking approach to drug discovery and development, significantly impacting the biotech industry. Their fearless and resilient pursuit of new science positions them as a key player in the field of RNA-targeted therapies, with a growing portfolio of achievements and a commitment to improving patient outcomes globally.